Your browser doesn't support javascript.
loading
The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 56-61, 2021.
Article in Chinese | WPRIM | ID: wpr-880031
ABSTRACT
OBJECTIVE@#To explore the impact of induction treatment response on the prognosis of pediatric core binding factor-acute myeloid leukemia (CBF-AML).@*METHODS@#The result of induce reaction and survival data of 157 pediatric CBF-AML patients in our hospital from September 2008 to December 2018 were retrospectively analyzed.The survival rate of the patients with different degrees of morphological remission after induction chemotherapy was comparative analyzed.@*RESULTS@#Among the 157 children with CBF-AML, 113 (72.4%) patients achieved morphologic leukemia-free state (MLFS) after the first course of induction chemotherapy, 153 (98.1%) patients achieved MLFS after the second course of induction chemotherapy. The 5-year event-free survival (EFS) rate and 5-year overall survival (OS) rate of patients with non-remission (NR) status after the first course of induction of chemotherapy was significantly lower than the patients achieved MLFS and the patients achieved partial remission (PR). The 5-year EFS rate and 5-year OS rate of the patients with PR status after the second course of induction chemotherapy were lower than the patients achieved MLFS, but the difference was not statistically significant. Multivariable analyze showed that NR after the first course of induction chemotherapy and myeloid sarcoma were the independent risk factors affecting EFS of the patients. There were six patients with NR status after the first course of induction chemotherapy, in which all of them harbored t(8;21), three of them with sex chromosome deletion, two of them with myeloid sarcoma.@*CONCLUSION@#NR status after the first course of induction chemotherapy was the independent risk factor affecting EFS and OS of CBF-AML patients, it can be taken as an indicator for higher risk stratification. PR status after the first course of induction chemotherapy may not be used as a diagnostic criterion for primary drug resistance.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Prognosis / Remission Induction / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Disease-Free Survival / Core Binding Factors / Induction Chemotherapy Type of study: Observational study / Prognostic study / Risk factors Limits: Child / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Prognosis / Remission Induction / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Disease-Free Survival / Core Binding Factors / Induction Chemotherapy Type of study: Observational study / Prognostic study / Risk factors Limits: Child / Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2021 Type: Article